Effects of irradiated tumor vaccine and infusion of granulocyte-macrophage colony-stimulating factor and interleukin-12 on established gliomas in rats

Jin Cherng Chen, Yun Chen, Jiann Ming Wu, Yen Hao Su, Kuo Feng Tai, Sheng Hong Tseng

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Purpose: We investigated granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-12 (IL-12) infused into the injection site of irradiated tumor vaccine (TV) as therapy for gliomas. Methods: Rats with subcutaneous RT-2 gliomas were treated with irradiated TV and/or subcutaneous infusion of GM-CSF and/or IL-12 via osmotic minipump 5 days after tumor-cell inoculation. Cytotoxic T lymphocyte (CTL) and natural killer (NK) cell activity were analyzed to investigate immune responses. Rats with intracerebral gliomas were treated with irradiated TV and infused GM-CSF/IL-12 3 days after tumor-cell inoculation. Tumor growth rates and animal survival were followed. Survivors were re-challenged with wild-type RT-2 cells subcutaneously or intracerebrally to study long-term anti-tumor immunity. Results: Rats with subcutaneous gliomas treated with GM-CSF and IL-12 or TV plus GM-CSF or IL-12 did not have increased survival rate (P > 0.2), but did have prolonged survival time (P < 0.05); in contrast, rats treated with TV plus GM-CSF/IL-12 had increased survival rate (P < 0.05) and prolonged survival time (P < 0.05) compared with controls. These treatment strategies showed enhanced CTL and NK cell activities. Rats with intra-cerebral gliomas treated with TV plus GM-CSF/IL-12 did not have increased survival rate (P = 0.11), but did have prolonged survival time (P < 0.0001). Survivors in each group were re-challenged with wild-type RT-2 cells, and all had long-term survival. Conclusions: Irradiated TV plus continuous localized infusion of GM-CSF/IL-12 may induce a tumor-specific anti-tumor immune response on established subcutaneous or intra-cerebral gliomas, and such a treatment strategy deserves consideration as adjuvant treatment for glioma.

Original languageEnglish
Pages (from-to)873-883
Number of pages11
JournalCancer Immunology, Immunotherapy
Volume55
Issue number7
DOIs
Publication statusPublished - Jul 1 2006
Externally publishedYes

Fingerprint

Cancer Vaccines
Interleukin-12
Granulocyte-Macrophage Colony-Stimulating Factor
Glioma
Neoplasms
Cytotoxic T-Lymphocytes
Natural Killer Cells
Subcutaneous Infusions
Active Immunotherapy
Interleukin-3
Immunity
Injections
Growth

Keywords

  • Glioma
  • GM-CSF
  • IL-12
  • Immunotherapy
  • Tumor vaccine

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Cancer Research

Cite this

Effects of irradiated tumor vaccine and infusion of granulocyte-macrophage colony-stimulating factor and interleukin-12 on established gliomas in rats. / Chen, Jin Cherng; Chen, Yun; Wu, Jiann Ming; Su, Yen Hao; Tai, Kuo Feng; Tseng, Sheng Hong.

In: Cancer Immunology, Immunotherapy, Vol. 55, No. 7, 01.07.2006, p. 873-883.

Research output: Contribution to journalArticle

@article{58f67e34d8b94d80a950f2d2938329e2,
title = "Effects of irradiated tumor vaccine and infusion of granulocyte-macrophage colony-stimulating factor and interleukin-12 on established gliomas in rats",
abstract = "Purpose: We investigated granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-12 (IL-12) infused into the injection site of irradiated tumor vaccine (TV) as therapy for gliomas. Methods: Rats with subcutaneous RT-2 gliomas were treated with irradiated TV and/or subcutaneous infusion of GM-CSF and/or IL-12 via osmotic minipump 5 days after tumor-cell inoculation. Cytotoxic T lymphocyte (CTL) and natural killer (NK) cell activity were analyzed to investigate immune responses. Rats with intracerebral gliomas were treated with irradiated TV and infused GM-CSF/IL-12 3 days after tumor-cell inoculation. Tumor growth rates and animal survival were followed. Survivors were re-challenged with wild-type RT-2 cells subcutaneously or intracerebrally to study long-term anti-tumor immunity. Results: Rats with subcutaneous gliomas treated with GM-CSF and IL-12 or TV plus GM-CSF or IL-12 did not have increased survival rate (P > 0.2), but did have prolonged survival time (P < 0.05); in contrast, rats treated with TV plus GM-CSF/IL-12 had increased survival rate (P < 0.05) and prolonged survival time (P < 0.05) compared with controls. These treatment strategies showed enhanced CTL and NK cell activities. Rats with intra-cerebral gliomas treated with TV plus GM-CSF/IL-12 did not have increased survival rate (P = 0.11), but did have prolonged survival time (P < 0.0001). Survivors in each group were re-challenged with wild-type RT-2 cells, and all had long-term survival. Conclusions: Irradiated TV plus continuous localized infusion of GM-CSF/IL-12 may induce a tumor-specific anti-tumor immune response on established subcutaneous or intra-cerebral gliomas, and such a treatment strategy deserves consideration as adjuvant treatment for glioma.",
keywords = "Glioma, GM-CSF, IL-12, Immunotherapy, Tumor vaccine",
author = "Chen, {Jin Cherng} and Yun Chen and Wu, {Jiann Ming} and Su, {Yen Hao} and Tai, {Kuo Feng} and Tseng, {Sheng Hong}",
year = "2006",
month = "7",
day = "1",
doi = "10.1007/s00262-005-0077-7",
language = "English",
volume = "55",
pages = "873--883",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "7",

}

TY - JOUR

T1 - Effects of irradiated tumor vaccine and infusion of granulocyte-macrophage colony-stimulating factor and interleukin-12 on established gliomas in rats

AU - Chen, Jin Cherng

AU - Chen, Yun

AU - Wu, Jiann Ming

AU - Su, Yen Hao

AU - Tai, Kuo Feng

AU - Tseng, Sheng Hong

PY - 2006/7/1

Y1 - 2006/7/1

N2 - Purpose: We investigated granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-12 (IL-12) infused into the injection site of irradiated tumor vaccine (TV) as therapy for gliomas. Methods: Rats with subcutaneous RT-2 gliomas were treated with irradiated TV and/or subcutaneous infusion of GM-CSF and/or IL-12 via osmotic minipump 5 days after tumor-cell inoculation. Cytotoxic T lymphocyte (CTL) and natural killer (NK) cell activity were analyzed to investigate immune responses. Rats with intracerebral gliomas were treated with irradiated TV and infused GM-CSF/IL-12 3 days after tumor-cell inoculation. Tumor growth rates and animal survival were followed. Survivors were re-challenged with wild-type RT-2 cells subcutaneously or intracerebrally to study long-term anti-tumor immunity. Results: Rats with subcutaneous gliomas treated with GM-CSF and IL-12 or TV plus GM-CSF or IL-12 did not have increased survival rate (P > 0.2), but did have prolonged survival time (P < 0.05); in contrast, rats treated with TV plus GM-CSF/IL-12 had increased survival rate (P < 0.05) and prolonged survival time (P < 0.05) compared with controls. These treatment strategies showed enhanced CTL and NK cell activities. Rats with intra-cerebral gliomas treated with TV plus GM-CSF/IL-12 did not have increased survival rate (P = 0.11), but did have prolonged survival time (P < 0.0001). Survivors in each group were re-challenged with wild-type RT-2 cells, and all had long-term survival. Conclusions: Irradiated TV plus continuous localized infusion of GM-CSF/IL-12 may induce a tumor-specific anti-tumor immune response on established subcutaneous or intra-cerebral gliomas, and such a treatment strategy deserves consideration as adjuvant treatment for glioma.

AB - Purpose: We investigated granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-12 (IL-12) infused into the injection site of irradiated tumor vaccine (TV) as therapy for gliomas. Methods: Rats with subcutaneous RT-2 gliomas were treated with irradiated TV and/or subcutaneous infusion of GM-CSF and/or IL-12 via osmotic minipump 5 days after tumor-cell inoculation. Cytotoxic T lymphocyte (CTL) and natural killer (NK) cell activity were analyzed to investigate immune responses. Rats with intracerebral gliomas were treated with irradiated TV and infused GM-CSF/IL-12 3 days after tumor-cell inoculation. Tumor growth rates and animal survival were followed. Survivors were re-challenged with wild-type RT-2 cells subcutaneously or intracerebrally to study long-term anti-tumor immunity. Results: Rats with subcutaneous gliomas treated with GM-CSF and IL-12 or TV plus GM-CSF or IL-12 did not have increased survival rate (P > 0.2), but did have prolonged survival time (P < 0.05); in contrast, rats treated with TV plus GM-CSF/IL-12 had increased survival rate (P < 0.05) and prolonged survival time (P < 0.05) compared with controls. These treatment strategies showed enhanced CTL and NK cell activities. Rats with intra-cerebral gliomas treated with TV plus GM-CSF/IL-12 did not have increased survival rate (P = 0.11), but did have prolonged survival time (P < 0.0001). Survivors in each group were re-challenged with wild-type RT-2 cells, and all had long-term survival. Conclusions: Irradiated TV plus continuous localized infusion of GM-CSF/IL-12 may induce a tumor-specific anti-tumor immune response on established subcutaneous or intra-cerebral gliomas, and such a treatment strategy deserves consideration as adjuvant treatment for glioma.

KW - Glioma

KW - GM-CSF

KW - IL-12

KW - Immunotherapy

KW - Tumor vaccine

UR - http://www.scopus.com/inward/record.url?scp=33645300066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645300066&partnerID=8YFLogxK

U2 - 10.1007/s00262-005-0077-7

DO - 10.1007/s00262-005-0077-7

M3 - Article

VL - 55

SP - 873

EP - 883

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 7

ER -